Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Recruiting

Phase 2

Cyclosporine & EltrombopagEarly Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Code:

NCT04304820

Conditions

Severe Aplastic Anemia

Eligibility Criteria

Sex: All

Age: 3 - 70+

Healthy Volunteers: Not accepted

Interventions

Eltrombopag

Cyclosporine

Horse-Anti-thymocyte-Globulin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-11. This information was provided to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI) on 2025-03-14.